Polycystic Kidney, Autosomal Dominant
27
1
2
22
Key Insights
Highlights
Success Rate
92% trial completion (above average)
Published Results
12 trials with published results (44%)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 27/100
7.4%
2 terminated out of 27 trials
91.7%
+5.2% vs benchmark
19%
5 trials in Phase 3/4
55%
12 of 22 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 22 completed trials
Clinical Trials (27)
Feasibility of Study of Empagliflozin in Patients With Autosomal Dominant Polycystic Kidney Disease
STOP-PKD: SGLT2-inhibition to Improve Prognosis in Polycystic Kidney Disease
Post-Marketing Surveillance Study of Tolvaptan in Patients With ADPKD
A Study of RGLS8429 in Patients With Autosomal Dominant Polycystic Kidney Disease
Time Restricted Feeding in Autosomal Dominant Polycystic Kidney Disease
A Medical Research Study Designed to Determine if Venglustat Can be a Future Treatment for ADPKD Patients
PErfusioN, OxyGen ConsUmptIon and ENergetics in ADPKD (PENGUIN)
A Safety, Pharmacokinetic & Dose-Escalation Study of KD019 in Subjects With Autosomal Dominant Polycystic Kidney Disease
Metformin as a Novel Therapy for Autosomal Dominant Polycystic Kidney Disease
Effect of Venglustat in Patients With Renal Impairment
Daily Caloric Restriction and Intermittent Fasting in Overweight and Obese Adults With Autosomal Dominant Polycystic Kidney Disease
Curcumin Therapy to Treat Vascular Dysfunction in Children and Young Adults With ADPKD
Ursodeoxycholic Acid as Treatment for Polycystic Liver Disease
Feasibility Study of Metformin Therapy in ADPKD
Wishing to Decrease Aquaresis in ADPKD Patients Treated With a V2Ra; the Effect of Regulating Protein and Salt
The Kidneys Ability to Concentrate and Dilute Urine in Patients With Autosomal Dominant Polycystic Kidney Disease
Long Term Safety of Immediate-release Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease
The Role of Endothelial Dysfunction in Adult Polycystic Kidney Disease
Effect of Tolvaptan on Renal Plasma Flow (RPF) and Glomerular Filtration Rate (GFR) in ADPKD
Pilot Study of RNA as a Biomarker for Autosomal Dominant Polycystic Kidney Disease